HYB-2055

immunomodulatory oligonucleotide, an agonist of toll-like receptor 9, for the potential treatment of cancer; in phase II clinical trials (8/2005)

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Lasek, Witold: 1 article (08/2005)
2.	Switaj, Tomasz: 1 article (08/2005)

1.	Neoplasms (Cancer) 08/01/2005 - "including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. "

1.	Toll-Like Receptor 9

1.	Injections